medigraphic.com
Revista Médica Sinergia

2021, Number 02

<< Back Next >>

Revista Médica Sinergia 2021; 6 (02)

Irritable bowel syndrome

Zeledón CN, Serrano SJA, Fernández AS

Language: Spanish
References: 18
Page: 1-13
PDF size: 238.83 Kb.


ABSTRACT

Irritable bowel syndrome is a frequent pathology in clinical practice. It is characterized by abdominal pain, alteration in bowel habit, bloating and flatulence. The Rome IV criteria are a tool to help the clinician define the diagnosis and the need to carry out tests on the patient. There is no specific cause identified, it is known that there is an alteration in the bidirectional brain-intestine axis which is influenced by multiple factors. There are 4 subtypes, irritable bowel syndrome with constipation, with diarrhea, mixed and nonspecific. According to the subtype, the best treatment is designated. There are pharmacological and non-pharmacological therapies that allow providing the patient with the multidisciplinary approach that this pathology requires due to its heterogenesis.


REFERENCES

  1. Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 29 de 2017;376(26):2566- 78.htps://doi.org/10.1056/NEJMra1607547

  2. Sultan S, Malhotra A. Irritable Bowel Syndrome. Ann Intern Med. 6 de junio de 2017;166(11):ITC8-96. https://doi.org/10.7326/AITC201706060

  3. Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. agosto de 2020;17(8):473-86. https://doi.org/10.1038/s41575-020-0286-8

  4. Defrees DN, Bailey J. Irritable Bowel Syndrome: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Prim Care Clin Off Pract. 1 de diciembre de 2017;44(4):655-71. https://doi.org/10.1016/j.pop.2017.07.009

  5. Grad S, Dumitrascu DL. Irritable Bowel Syndrome Subtypes: New Names for Old Medical Conditions. Dig Dis. 2020;38(2):122-7. https://doi.org/10.1159/000505287

  6. Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, et al. Guía de práctica clínica: síndrome del intestino irritable con estreñimiento y estreñimiento funcional en adultos: concepto, diagnóstico y continuidad asistencial. (Parte 1 de 2). Aten Primaria. 1 de enero de 2017;49(1):42-55. https://doi.org/10.1016/j.aprim.2016.11.003

  7. Mari A, Abu Baker F, Mahamid M, Sbeit W, Khoury T. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. marzo de 2020;9(3):685.https://doi.org/10.3390/jcm9030685

  8. Moayyedi P, Simrén M, Bercik P. Evidence-based and mechanistic insights into exclusion diets for IBS. Nat Rev Gastroenterol Hepatol. julio de 2020;17(7):406-13. https://doi.org/10.1038/s41575-020-0270-3

  9. Camilleri M. Sex as a biological variable in irritable bowel syndrome. Neurogastroenterol Motil. 2020;32(7):e13802. https://doi.org/10.1111/nmo.13802

  10. Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 1 de agosto de 2020;69(8):1441- 51. https://doi.org/10.1136/gutjnl-2020-321191

  11. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. marzo de 2015;110(3):444-54. https://doi.org/10.1038/ajg.2015.6

  12. Black CJ, Ford AC. Rational investigations in irritable bowel syndrome. Frontline Gastroenterol. 1 de marzo de 2020;11(2):140-7. https://doi.org/10.1136/flgastro-2019-101211

  13. Rawla P, Sunkara T, Raj JP. Updated review of current pharmacological and non-pharmacological management of irritable bowel syndrome. Life Sci. 1 de noviembre de 2018;212:176-81. https://doi.org/10.1016/j.lfs.2018.10.001

  14. Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. abril de 2019;2(1):6-29. https://doi.org/10.1093/jcag/gwy071

  15. Brenner DM, Sayuk GS. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Adv Ther. 1 de enero de 2020;37(1):83-96. https://doi.org/10.1007/s12325-019-01116-z

  16. Li B, Liang L, Deng H, Guo J, Shu H, Zhang L. Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020;11:332.https://doi.org/10.3389/fphar.2020.00332

  17. 17. Farmer AD, Wood E, Ruffle JK. An approach to the care of patients with irritable bowel syndrome. CMAJ. 16 de marzo de 2020;192(11):E275-82. https://doi.org/10.1503/cmaj.190716

  18. Brugnatelli V, Turco F, Freo U, Zanette G. Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment. Front Neurosci. 2020;14:371. https://doi.org/10.3389/fnins.2020.00371




2020     |     www.medigraphic.com